Home Featured Page 117

Featured

Latest

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten Years in the Making

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and What Comes Next; Pre-EO, DEA Poured Cold Water on Right to Try

God, Gabon, and Government: W. Bryan Hubbard on Ibogaine, the Executive Order, and What Comes Next

The Optimisation Problem: What Bryan Johnson’s 5-MeO-DMT Experiment Reveals About Psychedelics Going Mainstream

Reunion Neuroscience to Participate in the Oppenheimer Annual Healthcare Conference

Small Pharma Announces Further Positive Data from SPL026 Phase IIa Trial...

Numinus Wellness Inc. Executives to Present on Panel at Upcoming South...

atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates

Mindset Pharma and PharmAla Complete First Sale of Pharmaceutical Grade Psilocybin...

Psychedelic Bulletin #132: COMPASS Pathways Amends Phase 3 Program; Stamets Stack...

Webinar – Unraveling the Top 3 Psychedelic Neuroscience Myths

Webinar – A Somatic Perspective on Sex & Psychedelics: Focusing on...

Psychedelics Weekly – Cannadelic, Concussions, Vital, and More PT News

How To Get Your Start as a Psychedelic Informed Practitioner

EDITOR PICKS

Psilocybin for Cocaine Use Disorder: Peter Hendricks on a Trial Ten...

Pα+ Psychedelic Bulletin #224: Reactions to Trump’s Psychedelics Executive Order, and...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.